NEW YORK (GenomeWeb News) – Cancer biotherapeutics developer H3 Biomedicine said today that it will partner with Sage Bionetworks to develop new software aimed at supporting its efforts to predict human responses to certain drugs.

Cambridge, Mass.-based H3 said the software will couple its genomic and drug data with Sage's predictive modeling and collaborative capabilities to identify and predict associations between specific genetic alterations and drug response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.